Inizio Executive and Leadership Team

Ryan Hill, the Chief Financial Officer at Inizio, directs all global fiscal operations and capital allocation strategies. Overseeing the financial health of the organization, the Chief Financial Officer ensures alignment between investment in medical communications and long-term corporate growth. This leadership role involves managing complex budgetary requirements across five specialized business units to support the full product lifecycle for pharmaceutical clients. By optimizing resource distribution, Ryan Hill directly impacts the ability of the company to scale operations across international markets. Hill secures the financial stability necessary for sustained innovation in oncology and rare disease therapeutic areas. Through rigorous oversight of fiscal performance, the Chief Financial Officer maintains the economic foundation required for delivering high-impact commercialization services to the world's top 20 pharmaceutical companies while driving efficiency across all global divisions.

Dani Heywood, the Chief Operating Officer, STEM & Research Partnership at Inizio, manages the integration of scientific research capabilities with commercialization workflows. Overseeing the operational delivery of medical affairs and scientific communications, the Chief Operating Officer, STEM & Research Partnership ensures that clinical development data translates effectively into actionable market strategies. This leadership role involves coordinating cross-functional teams to support biotech and medical device organizations throughout the product lifecycle. By streamlining research partnerships, Dani Heywood directly impacts the speed and accuracy of medical communications delivered to healthcare professionals. Heywood drives operational excellence across complex therapeutic areas, including immunology and neuroscience. Through the synchronization of scientific expertise and commercial execution, the Chief Operating Officer, STEM & Research Partnership maintains the high standards of evidence-based engagement required to navigate the evolving global health landscape.

Martin Miguel, the Regional President, & Row, Inizio Engage (Japan) at Inizio, directs all commercial engagement activities within the Japanese market. Overseeing the expansion of healthcare professional engagement and patient support programs, the Regional President, & Row, Inizio Engage (Japan) ensures that local operations align with global commercialization standards. This leadership role involves tailoring marketing and communications strategies to meet the specific regulatory and cultural nuances of the regional life sciences landscape. By fostering strong relationships with local pharmaceutical and biotech entities, Martin Miguel directly impacts the success of product launches and market access initiatives. Miguel drives regional growth by leveraging the full suite of Inizio capabilities to address unique therapeutic needs. Through the management of local teams, the Regional President, & Row, Inizio Engage (Japan) secures a robust presence for the company within the critical Asian healthcare market.

Chris Savage, the Managing Director, Propensity4 and Chief of Staff at Inizio, architects strategic initiatives and manages internal organizational alignment. Overseeing the execution of high-level corporate projects, the Managing Director, Propensity4 and Chief of Staff ensures that the diverse business units operate with unified purpose. This leadership role involves bridging the gap between executive vision and daily operational output to enhance market access and commercial effectiveness. By facilitating communication across the leadership team, Chris Savage directly impacts the agility of the company in responding to pharmaceutical industry shifts. Savage drives the implementation of data-driven strategies that support the broader mission of delivering integrated solutions. Through the management of critical internal workflows, the Managing Director, Propensity4 and Chief of Staff sustains the operational momentum necessary for maintaining a competitive edge in the global health and life sciences sector.